# Daily Iteration Run — 2026-07-14 (Tue)

**Mode:** Automated scheduled run. No Monday weekly PubMed sweep (Tuesday).

## State
- Papers: 285 total — 272 VETTED / 13 FLAGGED / 0 unvetted (unchanged).
- Gaps: 15 tracked. Paths: 47 in research_paths; 56 validation records.

## Credibility Sweep (Step 4) — CLEAN
- Fabricated PMIDs (>=42,000,000) in scripts: 0.
- "zero SAEs" / "zero rejection" / "no rejection": 0.
- "cure/curative/achieves": all hits legitimate contextual usage (CAR-T cost-effectiveness discussion, ClinicalTrials.gov "T1D Cure & Cell Therapy" category labels) — no overstated preclinical claims.

## Work Queue Items Processed

### 1. validate_path — rituximab → T1D  →  reaffirmed PARTIALLY_VALIDATED
Stalest distinct PARTIAL path (last checked 2026-06-24). External evidence confirms:
- Rituximab delays C-peptide decline ~8.2 months at 1 year (NEJM 2009, PMID 19940299).
- Benefit persists at 2 years (Diabetes Care 2014, PMID 24026563 / PMC6410357).
- Extended follow-up: benefit disappears by ~30 months — decline rate parallels placebo. B-cell depletion alone does not alter underlying pathophysiology.
- No net-new RCT or systematic review since last check. Rating unchanged (PARTIAL).

### 2. audit_gap — Gap #11 (GOLD, last audited 2026-06-20) → reaffirmed OPEN
Intersection: Treg / CAR-Treg therapy combined with a personalized-nutrition / microbiome intervention as a single protocol.
- Direct-intersection publications: still ~0.
- 2026 CAR-Treg trials active (autoCD6-CAR-Treg, early-phase, recent-onset T1D) but NOT combined with a nutrition/microbiome protocol.
- 2025 reviews (IJMS PMC12609787; Springer Biol Proc Online PMC12661798) discuss both domains in one manuscript, not as a combined intervention. Microbiome-modulating-agent SR/MA (PMC11174426) is MMA-alone.
- Gap remains GOLD/open. No promotion, no weakening. Next audit ~2026-08-13.

## Pipeline Rebuild (Step 5) — PASS
`run_quality_improvements.py`: all 41 improvements [OK]; PMID verification against PubMed API passed.

## State & Sync (Step 6)
- Run recorded in state['run_history'] (91 runs). Queue reprioritized; follow-up path-validation item queued for next run.
- State saved to disk (backup: agent_state.json.bak_2026-07-14).
- Git commit/push: sandbox commit historically blocked by OneDrive .git/index.lock + missing GitHub auth. Push remains a USER action from local PowerShell (see queue item P1). 53+ commits unpushed as of last confirmed.

## Sources
- [Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function — NEJM 2009](https://www.nejm.org/doi/full/10.1056/NEJMoa0904452)
- [B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results — Diabetes Care 2014](https://diabetesjournals.org/care/article/37/2/453/29418/B-Lymphocyte-Depletion-With-Rituximab-and-Cell)
- [CAR T cell therapy in type 1 diabetes: what we know — PMC12661798](https://pmc.ncbi.nlm.nih.gov/articles/PMC12661798/)
- [Integrating Microbiome, Metabolomics, and Immunomodulation — IJMS 2025, PMC12609787](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12609787/)
- [Microbiome-Modulating Agents on T1D: SR & Meta-Analysis — PMC11174426](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11174426/)
